Pharmacokinetics of extended-release clarithromycin in patients with Mycobacterium ulcerans infection.
Humans
Clarithromycin
/ pharmacokinetics
Male
Female
Adult
Rifampin
/ pharmacokinetics
Middle Aged
Buruli Ulcer
/ drug therapy
Mycobacterium ulcerans
/ drug effects
Delayed-Action Preparations
/ pharmacokinetics
Anti-Bacterial Agents
/ pharmacokinetics
Aged
Young Adult
Area Under Curve
Tandem Mass Spectrometry
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 08 2024
28 08 2024
Historique:
received:
20
07
2023
accepted:
22
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
28
8
2024
Statut:
epublish
Résumé
Clarithromycin extended-release (CLA-ER) was used as companion drug to rifampicin (RIF) for Mycobacterium ulcerans infection in the intervention arm of a WHO drug trial. RIF enhances CYP3A4 metabolism, thereby reducing CLA serum concentrations, and RIF concentrations might be increased by CLA co-administration. We studied the pharmacokinetics of CLA-ER at a daily dose of 15 mg/kg combined with RIF at a dose of 10 mg/kg in a subset of trial participants, and compared these to previously obtained pharmacokinetic data. Serial dried blood spot samples were obtained over a period of ten hours, and analyzed by LC-MS/MS in 30 study participants-20 in the RIF-CLA study arm, and 10 in the RIF-streptomycin study arm. Median CLA C
Identifiants
pubmed: 39198495
doi: 10.1038/s41598-024-70890-w
pii: 10.1038/s41598-024-70890-w
doi:
Substances chimiques
Clarithromycin
H1250JIK0A
Rifampin
VJT6J7R4TR
Delayed-Action Preparations
0
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19963Informations de copyright
© 2024. The Author(s).
Références
Portaels, F., Silva, M. T. & Meyers, W. M. Buruli ulcer. Clin. Dermatol. 27, 291–305. https://doi.org/10.1016/j.clindermatol.2008.09.021 (2009).
doi: 10.1016/j.clindermatol.2008.09.021
pubmed: 19362692
van der Werf, T. S., Stinear, T., Stienstra, Y., van der Graaf, W. T. & Small, P. L. Mycolactones and Mycobacterium ulcerans disease. Lancet 362, 1062–1064. https://doi.org/10.1016/S0140-6736(03)14417-0 (2003).
doi: 10.1016/S0140-6736(03)14417-0
pubmed: 14522538
George, K. M. et al. Mycolactone: A polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283, 854–857 (1999).
doi: 10.1126/science.283.5403.854
pubmed: 9933171
Chauty, A. et al. Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob. Agents Chemother. 51, 4029–4035. https://doi.org/10.1128/aac.00175-07 (2007).
doi: 10.1128/aac.00175-07
pubmed: 17526760
pmcid: 2151409
Chauty, A. et al. Oral treatment for Mycobacterium ulcerans infection: Results from a pilot study in Benin. Clin. Infect. Dis. 52, 94–96. https://doi.org/10.1093/cid/ciq072 (2011).
doi: 10.1093/cid/ciq072
pubmed: 21148526
Nienhuis, W. A. et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: A randomised controlled trial. Lancet 375, 664–672. https://doi.org/10.1016/S0140-6736(09)61962-0 (2010).
doi: 10.1016/S0140-6736(09)61962-0
pubmed: 20137805
Phillips, R. O. et al. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. Antimicrob. Agents Chemother. 58, 1161–1166. https://doi.org/10.1128/AAC.02165-13 (2014).
doi: 10.1128/AAC.02165-13
pubmed: 24323473
pmcid: 3910847
Sarfo, F. S. et al. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob. Agents Chemother. 54, 3678–3685. https://doi.org/10.1128/AAC.00299-10 (2010).
doi: 10.1128/AAC.00299-10
pubmed: 20566765
pmcid: 2935024
Klis, S. et al. Long term streptomycin toxicity in the treatment of Buruli Ulcer: Follow-up of participants in the BURULICO drug trial. PLoS Negl. Trop. Dis. 8, e2739. https://doi.org/10.1371/journal.pntd.0002739 (2014).
doi: 10.1371/journal.pntd.0002739
pubmed: 24625583
pmcid: 3953024
Gurley, B. et al. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: Comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J. Clin. Pharmacol. 46, 201–213. https://doi.org/10.1177/0091270005284854 (2006).
doi: 10.1177/0091270005284854
pubmed: 16432272
pmcid: 1865122
Benedetti, M. S. Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugs. Pharmacol. Res. 32, 177–187 (1995).
doi: 10.1016/S1043-6618(05)80021-0
pubmed: 8866833
Eberl, S. et al. Role of p-glycoprotein inhibition for drug interactions: Evidence from in vitro and pharmacoepidemiological studies. Clin. Pharmacokinet. 46, 1039–1049. https://doi.org/10.2165/00003088-200746120-00004 (2007).
doi: 10.2165/00003088-200746120-00004
pubmed: 18027988
Chen, J. & Raymond, K. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann. Clin. Microbiol. Antimicrob. 5, 3 (2006).
doi: 10.1186/1476-0711-5-3
pubmed: 16480505
pmcid: 1395332
Alffenaar, J. W. et al. Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. Antimicrob. Agents Chemother. 54, 3878–3883. https://doi.org/10.1128/AAC.00099-10 (2010).
doi: 10.1128/AAC.00099-10
pubmed: 20585115
pmcid: 2935020
Guay, D. R. et al. Pharmacokinetics and tolerability of extended-release clarithromycin. Clin. Ther. 23, 566–577 (2001).
doi: 10.1016/S0149-2918(01)80060-6
pubmed: 11354390
Grau, S. et al. Impact of rifampicin addition to clarithromycin in Legionella pneumophila pneumonia. Int. J. Antimicrob. Agents 28, 249–252. https://doi.org/10.1016/j.ijantimicag.2006.03.029 (2006).
doi: 10.1016/j.ijantimicag.2006.03.029
pubmed: 16870401
Jacobson, M. A., Nicolau, D. P., Sutherland, C., Smith, A. & Aweeka, F. Pharmacokinetics of clarithromycin extended-release (ER) tablets in patients with AIDS. HIV. Clin. Trials. 6, 246–253. https://doi.org/10.1310/9FEX-MHQQ-74L6-GGCJ (2005).
doi: 10.1310/9FEX-MHQQ-74L6-GGCJ
pubmed: 16306031
Adler, J. L. et al. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of patients with acute exacerbation of chronic bronchitis. Clin. Ther. 22, 1410–1420 (2000).
doi: 10.1016/S0149-2918(00)83040-4
pubmed: 11192133
Murray, J. J. et al. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of adult patients with acute maxillary sinusitis. Clin. Ther. 22, 1421–1432 (2000).
doi: 10.1016/S0149-2918(00)83041-6
pubmed: 11192134
Phillips, R. O. et al. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: A randomised, open-label, non-inferiority phase 3 trial. Lancet 395(10232), 1259–1267. https://doi.org/10.1016/S0140-6736(20)30047-7 (2020).
doi: 10.1016/S0140-6736(20)30047-7
pubmed: 32171422
pmcid: 7181188
Olivares-Morales, A., Kamiyama, Y., Darwich, A. S., Aarons, L. & Rostami-Hodjegan, A. Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model. Eur. J. Pharm. Sci. 67, 32–44. https://doi.org/10.1016/j.ejps.2014.10.018 (2015).
doi: 10.1016/j.ejps.2014.10.018
pubmed: 25444842
Marsollier, L. et al. Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice. Antimicrob. Agents Chemother. 47, 1228–1232 (2003).
doi: 10.1128/AAC.47.4.1228-1232.2003
pubmed: 12654651
pmcid: 152492
Togami, K., Chono, S. & Morimoto, K. Distribution characteristics of clarithromycin and azithromycin, macrolide antimicrobial agents used for treatment of respiratory infections, in lung epithelial lining fluid and alveolar macrophages. Biopharm. Drug Dispos. 32, 389–397. https://doi.org/10.1002/bdd.767 (2011).
doi: 10.1002/bdd.767
pubmed: 21812004
Fish, D. N., Gotfried, M. H., Danziger, L. H. & Rodvold, K. A. Penetration of clarithromycin into lung tissues from patients undergoing lung resection. Antimicrob. Agents Chemother. 38, 876–878 (1994).
doi: 10.1128/AAC.38.4.876
pubmed: 8031063
pmcid: 284560
Gelber, R. H., Siu, P., Tsang, M. & Murray, L. P. Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. Antimicrob. Agents Chemother. 35, 760–763 (1991).
doi: 10.1128/AAC.35.4.760
pubmed: 1648889
pmcid: 245094
Vu, D. H. et al. Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS/MS. Talanta 121, 9–17. https://doi.org/10.1016/j.talanta.2013.12.043 (2014).
doi: 10.1016/j.talanta.2013.12.043
pubmed: 24607103
Vu, D. H., Alffenaar, J. W., Edelbroek, P. M., Brouwers, J. R. & Uges, D. R. Dried blood spots: A new tool for tuberculosis treatment optimization. Curr. Pharm. Des. 17, 2931–2939. https://doi.org/10.2174/138161211797470174 (2011).
doi: 10.2174/138161211797470174
pubmed: 21834763
Zent, C. & Smith, P. Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. Tuber. Lung Dis. 76, 109–113. https://doi.org/10.1016/0962-8479(95)90551-0 (1995).
doi: 10.1016/0962-8479(95)90551-0
pubmed: 7780091
Proost, J. H. & Meijer, D. K. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput. Biol. Med. 22, 155–163 (1992).
doi: 10.1016/0010-4825(92)90011-B
pubmed: 1617949
Portaels, F., Traore, H., De Ridder, K. & Meyers, W. M. In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob. Agents Chemother. 42, 2070–2073 (1998).
doi: 10.1128/AAC.42.8.2070
pubmed: 9687409
pmcid: 105863
Arenaz-Callao, M. P. et al. Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening. PLoS Negl. Trop. Dis. 13(1), e0007126. https://doi.org/10.1371/journal.pntd.0007126 (2019).
doi: 10.1371/journal.pntd.0007126
pubmed: 30689630
pmcid: 6366712
Ji, B. et al. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob. Agents Chemother. 50, 1921–1926. https://doi.org/10.1128/AAC.00052-06 (2006).
doi: 10.1128/AAC.00052-06
pubmed: 16723546
pmcid: 1479135